



## **Monoclonal Antibody against Human PAI-1 (3H3)**

**Catalog Number: 21070**

**Size: 100 µg**

**Host: Mouse**

### **Introduction to the Molecule**

Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activator, playing a major role in fibrinolysis<sup>1,2</sup>. PAI-1 is mainly produced by the endothelium, but is also secreted by other tissue types, such as adipose tissue<sup>3</sup>. It is normally present at low levels in plasma and tissue, but its expression and release are increased in various disease states (such as a number of forms of cancer), as well as in obesity and the metabolic syndrome<sup>4</sup>. PAI-1 is also involved in the pathophysiology of renal, pulmonary, cardiovascular, and metabolic diseases<sup>5-8</sup>. Elevated local or systemic PAI-1 can also exacerbate such pathologic conditions.

### **Purification**

Protein G affinity purification

### **Immunogen**

Recombinant human PAI-1 expressed in *E.coli*.

### **Specificity**

The antibody detects human PAI-1.

### **Formulation & Storage**

Liquid in phosphate-buffered saline (PBS). Store at -20°C for less than one week. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.

### **Application/Usage**

This antibody can be used as a capture antibody in a human PAI-1 ELISA in combination with polyclonal anti-human PAI-1 antibody as detection antibody.

### **References**

- [1] Lijnen HR, et al. (1995) *Baillieres Clin Haematol.* 8: 277-290
- [2] Dellas C, et al. (2005) *Thromb Haemost.* 2005; 93: 631-640
- [3] Binder BR, et al. (2002) *News Physiol Sci* 17:56-61
- [4] Vague P, et al. (1986) *Metabolism.* 35: 250-253
- [5] Sobel Be, et al. (2003) *Arterioscler Thromb Vasc Biol.* 23: 1979-1989
- [6] Eitzman DT, et al. (1996) *J Clin Invest.* 97(1):232-7
- [7] Gils A, et al. (2004) *Thromb. Haemost.* 91 (3): 425-37
- [8] Cale JM, Lawrence DA. (2007) *Curr Drug Targets.* 8(9):971-81